Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh Enters $207 Million Agreement for Biotheus EGFR/MET Bispecific

publication date: Nov 15, 2022

Jiangsu Hansoh Pharma acquired greater China rights to an EGFR/MET bispecific antibody from Zhuhai’s Biotheus in an $207 million agreement. Hansoh will be responsible for all costs necessary to develop PM1080 for cancer. It will pay $7 million upfront, up to $200 million in milestones and royalties on sales. Biotheus will retain ex-China rights to the drug, which has best-in-class potential and has shown good safety/efficacy profiles in previous pre-clinical tests. PM1080 is currently in GLP toxicity studies at Biotheus. More details....

Stock Symbol: (HK: 3692)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital